Ketamine and Methadone Supra- Regional Audit Presentation

Transcription

1 Ketamine and Methadone Supra- Regional Audit Presentation Audit Group: Alison Coackley, Anthony Thompson, Graham Whyte, Helen Bonwick, Ruth Clark, Agnes Noble, Aileen Scott, Andrew Dickman, Sarah Fradsham External Experts: Dr Anne Garry, Dr Kosta Levshankov

2 Background to audit Methadone re-audit New ketamine audit Supra- regional Two parts:- Health care professionals questionnaire, Prospective data collection in individual units

3 Plan for Presentation Methadone: Current Standards, Literature review, Audit results. Ketamine: Literature review, Audit results. Standards and Guidelines for methadone and ketamine. Comments from external experts Discussion

4 Ketamine literature review September 2012 Dr Anthony Thompson

5 Ketamine Revision Class general anaesthetic Indications anaesthesia, pain unresponsive to standard treatments Contraindications any situation where raised Blood Pressure/Intracranial pressure is hazardous. Acute Porphyria

6 Pharmacology 1 NMDA receptor channel complex Involved in developing central sensitisation of dorsal horn neurones which transmit pain signals At rest the channel is blocked by Magnesium ions

7 Pharmacology 2 But if prolonged stimulus and excitation the channel unblocks and Calcium moves into the cell This causes neuronal hyper excitability and reduction on opioid responsiveness, hyperalgesia and allodynia

8 Pharmacology 3 KETAMINE is the most potent NMDA receptor channel blocker available clinically Binds to the channel sites when open and activated Antagonises the hyper excitation state

9 Pharmacology 4 Multiple receptor activities Interacts with other calcium, sodium channels Dopamine receptors, cholinergic transmission, noradrenergic and serotonergic re-uptake and opioid-like and antiinflammatory effects

10 Pharmacology 5 Commercially available Ketamine is equal enantiomers of S(+) and R(-) forms of the drug Bioavailability - parenterally 93%, orally 17% Oral Ketamine Norketamine (equipotent)

11 Pharmacokinetics Bioavailability 93% intramuscular (im), 45% nasal, 30% sublingual, 30% PR, 20% oral (PO) Onset 5min im, min s/c, 30 min PO t ½ h im, 3h PO, Duration 30min-2h im, 4-6h PO

12 Cautions Psychiatric disorder, epilepsy, glaucoma, hypertension, cardiac failure, history of strokes Plasma concentration raised by diazepam, CYP3A4 inhibitors e.g. clarithromycin, ketoconazole

13 Undesirable effects Dose related Psychomimetic euphoria, dysphasia, blunted affect, vivid dreams and nightmares, inattention, memory, illusions, hallucinations, altered body image Delirium, dizziness, diplopia, blurred vision, nystagmus, hearing, HYPERTENSION, tachycardia, hyper salivation, nausea and vomiting, injection site erythema, URINARY TRACT TOXICITY

14 Urinary tract toxicity 1 Unclear of cause, direct irritation or metabolites Frequency, urgency, urge incontinence, dysuria, haematuria Interstitial cystitis, detrusor over activity, reduced bladder capacity, vesico-ureteric reflux, hydronephrosis, papillary necrosis, renal impairment

15 Urinary tract toxicity 2 If symptoms of urinary tract infection and NO evidence of bacterial infection, consider discontinuing and seeking Urology review Symptoms settle in a few weeks, gradual reduction in dose ideally to prevent pain escalation

16 The Literature Review

17 Cochrane Collaboration 2009 Bell, Eccleston and Kalso 2009 To determine the effectiveness of ketamine as an adjuvant to opioids in the treatment of cancer pain Medline, embase, cancerlit, Cochrane library Selection criteria adult, cancer, on opioid, received ketamine or placebo/active control

18 Cochrane Collaboration 2009 Data 4 RCTs (2 excluded, poor design) and 32 case studies Results 2 trials included, small numbers of patients Conclusion More RCTS needed, current evidence insufficient

19 Results 2 studies Mercandante 2000, Italy, Placebo, 3 hour trial Yang 1996, Taiwan, Morphine active control Both cross over trials

20 Mercandante patients 7 men 3 women years Pain unrelieved by morphine Diagnosed with neuropathic pain

21 Mercandante doses ketamine IV bolus 0.25mg/kg and 0.5mg/kg as adjuvant vs. normal saline 2 day washout between treatments No rescue doses described

22 Outcomes Mercandante 2000 Pain score at 30, 60, 90, 120, 180 minutes and adverse effects Pain score 0-10

23 Effectiveness 0.25mg/kg dose Mercandante 2000 Pain score reduced after 30 mins vs. normal saline After 60 mins effect lessened but some benefit even after 180 mins noted

24 0.5mg/kg dose Mercandante 2000 Significant reduction at 30 mins and maintained throughout the 180 mins

25 Yang hospital patients 10 men 10 women Cancer pain effectively treated with morphine

26 Yang 1996 Assessed intrathecal 1mg/kg ketamine as adjuvant vs. morphine alone Morphine dose titrated until stable 48 hours then randomly crossed over to morphine PLUS Ketamine or continued on morphine (control) alone, administered twice daily intrathecally No washout period Rescue doses available Morphine 5mg im

27 Yang 1996 Outcomes Patient pain score 0-10 Pain frequency Morphine dose Total morphine dose Total rescue doses Frequency of intrathecal titration

28 Yang 1996 Co-administration of ketamine reduced the dose of morphine needed Was as effective as intrathecal morphine alone

29 Adverse effects No withdrawals in either study Hallucinations commonest treated with diazepam Mild effects including light flashes, buzzing in head, insobriety, drowsy, nausea and vomiting, dry mouth, confusion

30 Conclusions No evidence based conclusion due to small numbers

31 32 case studies Opioid AND ketamine 246 patients Other Reports Various routes used po,im,s/c,iv,s/c infusion, epidural, intrathecal Various doses 1mg/kg/day s/c infusion to 600mg/day iv, 67.2mg/day intrathecal Various time scales 4 hours to 12 months

32 Case Studies Most used morphine, some fentanyl, hydromorphone, diamorphine or alone 16 reports described dramatic relief of refractory cancer pain Commonest adverse effects sedation and hallucinations One had sedation settling with opioid reduction Only 2 studies out of 32 had patient withdrawal

33 Case studies Inflamed infusion sites, nystagmus, hyperalgesia post cessation Post mortem myelopathy post intrathecal infusion with vasculitis Lloyd Williams s/c infusion sites, 0.1% hydrocortisone cream to maintain sites

34 Therapeutic Review Rachel Quibell, Eric Prommer, Mary Mihalyo, Andrew Wilcock and Robert Twycross Journal of Pain and Symptom Management Volume 41, March 2011 PCF 4 Chapter 13 Anaesthesia Page

35 Dose and Use Therapeutic Review Advise long term ketamine only if Burst has failed Due to renal tract concerns

36 50mg/5ml Co-administration Oral Ketamine 10-25mg TDS/QDS and PRN Titrate up in steps to 100mg QDS Consider dose reduction if drowsy/psychomimetic issues Can be opioid sparing effect

37 Oral Ketamine Some centres attempt withdrawal over several weeks Benefit can persist with out ketamine for weeks/months

38 Maximal dilution 0.9% saline 100mg/24 hrs. Burst Ketamine If not effective increase to 300mg/24 hrs. If not effective again, increase to 500 mg/24 hrs. Stop 3 days after last dose increment Prophylactic use

39 Other Routes Sublingual (s/l) Subcutaneous stats (s/c) Intravenous (IV) Continuous IV Infusion (CIVI)

40 Opioid reduction Some centres reduce regular opioid dose 25-50% when starting parenteral ketamine

41 Other Papers of Interest The use of Ketamine in severe cases of refractory pain syndromes in the palliative care setting : A case series Kerr et al, Buffalo, New York Journal Of Palliative Medicine, Volume 14, Number 9, complex cases, non-cancer

42 Sub-anaesthetic doses unresponsive to escalating opioid doses Sickle cell, paraplegia, multiple issues including Chronic Obstructive Pulmonary Disease, Ischaemic heart disease, Raynaud`s, quadriplegia 2 used CIVI, 2 used CSCI Ketamine Conclusion ketamine has a role in reducing opioid tolerance and hyperalgesia, few side effects

43 Kate Jackson et al, Victoria, Australia 2001 Burst Ketamine for refractory cancer pain: an open label audit of 39 patients (J. Of Pain and Symptom Management Vol. 22 No 4 p834) 2010 The effectiveness and adverse effects profile of Burst Ketamine in refractory cancer pain (J. of Palliative acre Autumn 2010;26,3)

44 2001 Study Multi centre unblinded open label audit39 patients 18 month study, 4 Pall Care Centres Short duration Ketamine (3-5 days) 100mg-300mg-500mg per 24 hours CSCI 43 pains 29 responded Response rate 67% 24/29 maintained good pain control (8 week max.)

45 2001 Study 12 had adverse Psychomimetic effects Dose related Cancer patients Taking opioid, NSAIDS and neuropathic agents Suggested need for further investigation into the place of Ketamine in cancer pain management

46 2010 Study The VCOG PM1-100 Study Multi centre study Response rate 22/44 i.e. 50% 100mg-300mg-500mg per 24 hrs. CSCI Would the early promising results continue Open label study of effectiveness and incidence of adverse effects (AE) 53 patients registered, 44 eligible aged 35-82, 21 men 23 women

47 2010 Study 77% needed 300mg or more, 41% needed 500mg Response rate dropped to 50% but 9% had complete response (pain free) Ketamine role not purely for neuropathic pain, but bone metastases with nerve damage Dose related AE Cardiovascular stability noted

48 Need RCTs Blinded 2010 Study Conclusions Limited opportunities in Palliative Care Difficult to blind with AE being noticeable The lack of level I and II evidence should NOT preclude the use of Ketamine Burst Treatment

49 Other Nuggets Burst Ketamine to reverse opioid tolerance in cancer pain Letter to editor, Mercandante, J. Pall. Med. Vol. 25 No. 4 p Case reports Hyper excited opioid excess state Ketamine as co-analgesic OR reversal of opioid tolerance

50 Ketamine Mouthwash 1 Cooney et al EAPC 2011 Palliative Care Department, Dooraradoyle, Limerick Retrospective study 12 months Patients who received the mouthwash Dose, number of doses, duration, concurrent analgesics, adverse effects

51 Ketamine Mouthwash 2 Received Ketamine 20mg in 10ml Bioxtra mouthwash, 6 hourly, swish and spit All were head and neck, post radiotherapy (DXT) Useful and safe Mild stinging when first used only

52 Ketamine Mouthwash 3 Slatkin et al, Pain Medicine, Volume 4, number 3, 2003 Duarte, California Topical ketamine in the treatment of mucositis pain Case study, 32 year old lady, DXT Unclear if local or systemic effect Anti-inflammatory? Sodium channel?

53 Mercandante Letter 2003 Possible hyperalgesic effect of opioids NMDA receptor involved Development of this reversed/shifted by NMDA antagonists Wind up increased neuronal response to repeated stimuli Ketamine inhibits this wind up Reversal of central changes resets the nerve system

54 A Randomised Controlled Trial D.Currow, J Hardy et al Brisbane, Sydney, Adelaide Randomised double blind controlled multi centre study of subcutaneous ketamine in the management of cancer pain

55 Currow and Hardy et al Stable opioid dose Severe pain Adequate co-analgesics Randomised to Placebo or Ketamine mg per 24 hrs. CSCI Response greater than 2 point drop in BPI scale Pain score day 6 end point

56 Currow and Hardy et al Results 185 patients March February 2011 High placebo response 26/92 (28%) with no difference between placebo and active arms Trial does NOT support the role of s/c Ketamine in the treatment of cancer pain in advanced cancer

57 Urinary tract damage Storr et al, Cumbria, Palliative Medicine, 2009 ; 23: Describes 3 cases developing significant urological symptoms Case 1- oral 50mg QDS Case 2 oral 170mg QDS Case 3 oral 200mg QDS Temporal link

58 Refractory Depression Intravenous Ketamine Burst for refractory depression in a patient with advanced cancer Stefanczky-Saphieha et al, J. Palliative Medicine, Vol. 11, No.9, 2008, Toronto Studies in non cancer suggest NMDA antagonist role in rapid improvement from severe depression, even single Iv doses Burst Ketamine used with success for major depressive disorder in advanced cancer Suggest RCTs

59 Role of Ketamine in Analgesia Literature review, Legge et al, West Virginia, USA American society of consultant pharmacists vol.21, issue 1, 2006 Medline, Cochrane Conclusion Useful with Opioids

60 Palliative Sedation Letter J. of Pain and Symptom management Vol.36 no.4 October 2008 Carter et al, Bristol Case study 100mg IV, 300mg agitated, settled with 500mg rapidly IV Monotherapy role (?)

61 Conversion from s/c to oral J. of Pain and Symptom management. Vol.41, No.6, June 2011 Benitez-Rosario et al, Tenerife A strategy for conversion from s/c to oral Ketamine in Cancer Patients: Effect of a 1:1 Ratio 29 patients enrolled Stable on s/c ketamine

62 Conversion from s/c to oral Converted to oral ketamine for maintenance Mean s/c dose 300mg/24 hours Used 1:1 ratio Given TDS Close monitoring No adverse effects reported

63 And finally from me

64 Systematic review Hocking and Cousins Ketamine in chronic pain management: an evidence based review Anaesthetic Analgesia. 2003;97: Good therapeutic response to parenteral ketamine suggests oral response

65 Ketamine and Methadone Practice and Experience Survey Supra Regional Survey Monkey Questionnaire Ketamine 50 responses Methadone 46 responses Dr Graham Whyte

66 Ketamine Results (n=50) 66

67 67

68 68

69 Yes 58% No 40% 69

70 70

71 Professions involved in starting Ketamine in last 12months Confidence by profession Consultants 85% StR 78% SSAS 80% CNS 21% Consultants 8.4/10 StR s 5.6/10 SSAS 5.4/10 CNS 1.6/10 71

72 Methadone Comparative Professional Group % Converted to Methadone past 12 months Consultant 54% 6.8/10 StR 38% 4.8/10 SSAS 60% 5.6/10 CNS 0% 1.6/10 Average Confidence Level in Initiating Methadone 72

73 73

74 Examples of doses used: Haloperidol-burst ketamine 3mg in driver with ketamine oral ketamine - 1.5mg nocte and PRN available Haloperidol oral and sc- 1.5mg stat or up to 5mg over 24 hours Diazepam oral 2.5 mg up to tds Midazolam sc 2.5-5mg stat and 5-10mg via CSCI If giving Ketamine orally I would prescribe oral haloperidol mg od. If giving Ketamine s/c I may prescribe S/C haloperidol 3-5mg but may also give it orally 74

75 What route of administration do you use? Equal preference for Burst and Oral Ketamine Burst 100mg/24 hours upto 500mg/24 hrs 5-7 days Oral 10 mg tds most common dosage. 75

76 Burst ketamine; easier to administer and control in the inpatient setting severe - burst, less severe- oral/if low mood like oral too Oral ketamine as regime I am most familiar with My experience is primarily with burst ketamine so I would have preference for this Depends on the patient and no preferred regime 76

77 77

78 78

79 79

80 Prospective data collection of current practice : Ketamine results Dr Aileen Scott

81 ICN

82 Sex

83 Age

84 Diagnosis

85 Setting

86 Is this the patient s first use of ketamine?

87 Indication for ketamine

88 Pre-use checks

89 Route used

90 Ketamine mouthwash Used in one patient for oral mucosal pain No concurrent medication prescribed Commenced at 10mg BD and continued and discharged on this dose

91 Reasons for using oral ketamine

92 Oral ketamine Starting dose range 5-20mg TDS Maximum dose range mg TDS

93 Reasons for using subcutaneous ketamine

94 Burst ketamine regimens Starting dose range: mg over 24 hours Maximum dose range: mg over 24 hours

95 Burst ketamine Additional medications prescribed

96 Subcutaneous infusion regimens Starting dose range: mg over 24 hours Maximum dose range: mg over 24 hours Various regimens used Titrated in increments of 50mg and 100mg over varying numbers of days In 2 cases doses did not change

97 Subcutaneous ketamine Additional medication prescribed

98 Diluent used

99 Checks after ketamine commenced

100 Were any side effects observed?

101 What adjuvants were used prior to starting ketamine?

102 How much opioid was the patient on prior to starting ketamine?

103 Did the patient s opioid dose change following commencement of ketamine?

104 Patients converted from SC to oral ketamine Patient 1 100mg/24 hours to 20mg TDS Patient 2 500mg/24 hours to 10mg TDS Patient 3 400mg/24 hours to 10mg TDS

105 Was the patient discharged on ketamine?

106 On discharge, who was provided with information about ketamine?

107 What follow-up was arranged for the patient?

108 Was the patient pain-free at 4 weeks?

109 Ketamine Standards and Guidelines Dr Sarah Fradsham

110 General principles in the Use of Ketamine

111 Introduction Ketamine is a drug used for the induction and maintenance of general anaesthesia Ketamine has a role in treatment of pain unresponsive to standard treatments (e.g. neuropathic, inflammatory, ischaemic, procedural pains) 1,2,3 Ketamine is a dissociative anaesthetic with analgesic properties at sub-anaesthetic doses 3,5

112 The NMDA receptor channel is involved with sensitisation of the dorsal horn neurones which transmit pain signals. Prolonged stimulation (pain) causes hyper excitability and reduced opioid responsiveness, hyperalgesia and allodynia 4.

113 Ketamine is a potent NMDA receptor channel blocker, as well as other actions on the following channels calcium, sodium, dopamine, cholinergic, noradrenergic, serotonergic reuptake and opioid-like effects and anti-inflammatory effects 6,7

114 Ketamine has been used as an analgesic in many clinical settings including post-operative, chronic non-cancer pain, cancer pain, and procedural pain (e.g. burns dressings) and painful mucositis 8,9. in cancer pain, ketamine has been used mainly ORALLY (PO) or SUBCUTANEOUSLY (CSCI)

115 Subcutaneous use can be Burst (see below) or more prolonged subcutaneous use. Side effects are dose related. 40% occurrence with CSCI, less so with PO. Ketamine abuse is common on the street and associated with adverse media attention as a result.

116 Ketamine can cause urinary tract problems, tachycardia, hypertension and intracranial hypertension and Psychomimetic side effects e.g. vivid dreams, hallucinations, altered body image and mood. These psychomimetic side effects can be managed with Midazolam and/or haloperidol. Co-administration is recommended 11,12 (see manufacturers PI)

117 Ketamine undergoes extensive first pass metabolism Mainly to Norketamine As an analgesic it is equipotent to parenteral ketamine 10

118 Less than 10% is excreted unchanged, half in the faeces and half renally. Norketamine is renally excreted and long term use leads to hepatic enzyme induction and enhanced ketamine metabolism.

119 Formulations and Supply Oral solution Made to order Sugar free Made to order Martindale e.g 50mg/5ml (other strengths are avaliable) Different flavours Unlicensed

120 Preparation of oral Ketamine:Pharmacy Guidelines Use 100mg/ml 10ml vials (cheapest) To prepare 100ml 50mg/5ml oral solution 10ml vial of ketamine 100mg/ml 90ml purified water Refrigerate Use within a week of manufacture Not recommended to do in ward environment

121 Injectable preparations Pfizer 10mg/ml 20ml ampoule 50mg/ml 10ml ampoule 100mg/ml 10ml ampoule Off label

122 Guidelines

123 Guidelines Ketamine for pain control should be initiated by a Palliative care physician experienced in the use of ketamine. This is usually done in a specialist palliative care inpatient unit. [Level 4] The majority of the evidence for the use of ketamine for pain control supports the use of burst ketamine. This is therefore recommended as first line treatment. Long term ketamine is only recommended if burst ketamine has failed due to concerns regarding urinary tract toxicity. [Level 4] Suggested doses and regimes are described in Table 1.

124 Table 1- Doses and Regimens [Level 4]

125 Guidelines cont Compatibility in syringe drivers [Level2] For subcutaneous regimens it is recommended that ketamine is diluted with sodium chloride 0.9%. When giving subcutaneous ketamine via a syringe driver it is compatible with morphine plus additional drugs when mixed with sodium chloride 0.9% 13. Box A describes compatibility data for drug mixtures containing ketamine.

126 Box A. Compatibility data

127 Guidelines- Monitoring Ketamine can cause tachycardia and intracranial hypertension. Due to this the blood pressure and pulse rate should be checked prior to the commencement of ketamine and twice daily during the dose titration phase or throughout the duration of burst ketamine. [Level 4] If the pulse rate rises above 20bpm from baseline or above 100bpm or the the blood pressure rises by 20mmHg on consecutive readings, a dose reduction should be considered. If the pulse rate or blood pressure does not return to baseline readings with a dose reduction then ketamine should be discontinued. [Level 4]

128 Guidelines- Monitoring As ketamine has an opiate sparing effect, patients should be monitored for signs of opiate toxicity. During the dose titration phase this should include twice daily monitoring of respiratory rate along with blood pressure and pulse rate as described above. The patients conscious level should also be monitored and if there is any concern regarding opiate toxicity the patient should be reviewed by a clinician and consideration of a dose reduction of the regular opiates should be made. [Level 4] ( see opiate reduction below)

129 Guidelines- Monitoring To assess the effectiveness of ketamine patients should have pain scores recorded prior to the commencement of ketamine and twice daily during the dose titration phase. This will help to establish whether further incremental increases in the doses are needed. Pain scores should also be recorded at follow up reviews for patients on long term ketamine or those that have received burst ketamine to establish ongoing effectiveness of pain control. [Level 4] For those patients maintained on long term ketamine reassessment should be carried out by a palliative care specialist monthly or sooner depending on symptoms or clinical need. [Level 4]

130 Guidelines- Opioid reduction As ketamine has an opiate sparing effect a dose reduction of 25% should be considered in those patients commencing parenteral or oral ketamine or if patients develop signs of opiate toxicity. [Level 4] All units commencing ketamine should ensure naloxone is available for use in the case of respiratory depression associated with opiate overdose/ toxicity. [Level 4] Use of ketamine is not recommended in patients on transdermal opioids due to the risk of opiate toxicity. In these patients an opiate conversion should be considered prior to commencing ketamine. [Level 4]

131 Guidelines- Conversions [Level 4] Evidence regarding conversions is limited however, when converting from PO ketamine to Subcutaneous ketamine for use in a CSCI, a conversion of 1:1 is suggested PO ketamine undergoes extensive first pass hepatic metabolism to norketamine which provides the main analgesic effect. The maximum blood concentration of norketamine is greater after PO administration than after parenteral administration therefore when converting from SC:PO a conversion of 3:1 is suggested. In both cases, there should be the provision for close monitoring and ability to alter the dose as necessary.

132 Guidelines- Adjuvant medications Ketamine can cause undesirable psychomimetic effects such as hallucinations, euphoria, vivid dreams which can be distressing to patients. It is therefore suggested that ketamine is given concurrently with midazolam or haloperidol to control any undesirable effects. [Level 4] Suggested doses include Haloperidol 2mg-5mg po nocte or 2mg-5mg via CSCI over 24hrs or Midazolam 5mg-10mg via CSCI. [Level 4]

133 Guidelines- Urinary Toxicity Ketamine has been linked to urinary tract toxicity including interstitial cystitis, papillary necrosis and renal impairment. If a patient develops symptoms of a urinary tract infection and there is NO evidence of bacterial infection consider discontinuing the ketamine. The patient may require a urology review. [Level 4]

134 Guidelines- Discharge Patients discharged on ketamine should be followed up by a specialist palliative care clinician within 4 weeks to review pain control. [Level 4] Dose alterations of ketamine should be undertaken in a specialist inpatient unit or after specialist palliative care outpatient review. [Level 4] When a patient is discharged on ketamine standardised information should be give to the patients, GP and community pharmacist. [Level 4]

135 Guidelines Discharge Units should liaise with the patients GP and community pharmacy prior to discharge to confirm future supplies of ketamine. [Level 4] Patients on oral ketamine should be aware that they need to request a repeat prescription at least 7 days in advance of their own supply running out. [Level 4] Units should consider the use of a ketamine card to be given to patients on discharge to inform other health professionals that the patient is on ketamine. [Level 4]

136 Standards

137 Standards The decision to commence ketamine, the indication and regimen to be used should be clearly documented in the patient s case notes. [Grade D] Prior to commencing ketamine, the patient s heart rate, blood pressure, respiratory rate and pain score should be recorded. These should be rechecked twice daily until ketamine is discontinued or the titration is complete. [Grade D] If administering ketamine via a subcutaneous infusion, then sodium chloride 0.9% should be used for dilution. [Grade D] Ketamine should always be prescribed in milligrams (mg). [Grade D]

138 Standards If a patient is discharged on ketamine, the discharge letter should include a named contact and telephone number for further advice. [Grade D] For patients who are discharged on ketamine, units should have standardised information to give to the patient, their GP and community pharmacist. [Grade D] Patients discharged on ketamine (oral or subcutaneous) should have at least monthly follow-up with a Palliative Medicine clinician experienced in the use of ketamine. [Grade D] Specialist Palliative Care units should have a policy for the use of ketamine as an analgesic. [Grade D]

139 Ketamine References 1. Persson J et al The analgesic effect of racemic ketamine in patients with chronic ischaemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesilogica Scandinavica 42: Graven-Nielsen T et al (2000) Ketamine reduces muscle pain, temporal summation and referred pain in fibromyalgic patients. Pain 85: Visser E and Schug SA (2006) The role of Ketamine in pain management Biomed pharmocother. 60 :

140 4. Elliott K et al (1994) The NMDA receptor antagonists, LY and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not kappa opioids. Pain. 56 : Fallon MT and Welsh J (1996) The role of ketamine in pain control. European Journal of Palliative Care. 3: Meller S et al (1996) Ketamine : relief from chronic pain through actions at the NMDA receptor? Pain. 68:

141 7. Kawasaki C et al (2001) Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood. Can J Anaesthes. 48 : Richardson P and Mustard L (2009) The management of pain in the burns unit. Burns. 35 : Slatkin NE and Rhiner M (2003) Topical ketamine in the treatment of mucositis pain. Pain Medicine. 4:

142 10. Hizaji Y et al (2002) Contribution of CYP3A4, CYP2B6 and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metabolism & Disposition. 30 : Chu PS et al (2008) The destruction of the lower urinary tract by ketamine abuse : anew syndrome? BJU Int. 102 : Palliative Care Formulary Quibell R et al. Therapeutic review: Journal of Pain and Symptom Management Volume 41, March Dickman A. Drugs in palliative care. OUP.

143 Time to hear from the experts...

144 Any Questions?